All In Biotech

Drug Trial Radar · NCT07008456

A Study to Investigate the Efficacy and Safety of Two Different Doses of Twice Daily Distal Jejunal-release Dextrose Beads Formulations Combined With a Gel Composition Compared to Placebos in Obese Subjects With Weight Related Comorbidities

A Phase II Study to Investigate the Efficacy and Safety of Two Different Doses of Twice Daily Distal Jejunal-release Dextrose Beads Formulations (APHD 012 and APHD 002) Combined With a Gel Composition, Compared With Two Different Doses of the Placebo Beads Formulations (APHP 012 and APHP 002) Combined With a Gel Composition in Obese Subjects With Weight Related Comorbidities

Last checked: Nov 19, 2026Latest source record: Sep 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

102

Planned (sponsor's estimate)

Start

Sep 12, 2025

Primary completion

Jul 2026

Study completion Jul 2026

Sponsor

Lead sponsor
Aphaia Pharma US LLCIndustry
Sponsor type
Industry
First posted
Jun 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this randomized, double-blind, placebo-controlled, phase IIa study is to demonstrate superiority on body weight reduction of two different doses of twice daily distal jejunal-release dextrose beads formulations (APHD 012 and APHD 002) combined with a gel composition, compared with two different doses of the placebo beads formulations (APHP 012 and APHD 002) combined with a gel composition in obese subjects with weight related comorbidities.

Conditions

  • Obese With Comorbidities
  • Obese Patients (BMI ≥ 30 kg/m²)

Interventions

  • APHD-012Drug

    12 g dextrose beads

  • APHD-002Drug

    2 g dextrose beads

  • APHP-012Drug

    12 g placebo beads

  • APHP-002Drug

    2 g placebo beads

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Body weightTime frame: 24 weeks

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • LTD "Israeli-Georgian Medical Research Clinic Healthycore"

    Tbilisi, K'alak'i T'bilisi, Georgia · Recruiting

  • LTD "New Hospitals"

    Tbilisi, K'alak'i T'bilisi, Georgia · Recruiting

  • LTD "Acad. G. Chapidze Emergency Cardiology Center"

    Tbilisi, K'alak'i T'bilisi, Georgia · Recruiting

  • LTD "Diacor"

    Tbilisi, K'alak'i T'bilisi, Georgia · Recruiting

  • NNLE "Jo Ann University Hospital"

    Tbilisi, K'alak'i T'bilisi, Georgia · Recruiting

  • LTD The First Medical Center

    Tbilisi, K'alak'i T'bilisi, Georgia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.